Tissue factor-targeted antibody-drug conjugates in cervical cancer: Focus on tisotumab vedotin.
Cervical cancer remains a major global health burden, and treatment options after progression of recurrent or metastatic disease remain limited. Tisotumab vedotin (TV) is a tissue factor-directed antibody-drug conjugate that delivers monomethyl auristatin E after target binding and internalization. In innovaTV 204, TV...